CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...
Phase 3
Tatabanya, Hungary and 75 other locations
PAKT was an investigator-led, placebo-controlled, randomized phase II trial performed in 42 academic medical centers in the United Kindom, South Kore...
Phase 2
Budapest, Hungary and 45 other locations
the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple...
Phase 3
Budapest, Hungary and 136 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...
Phase 3
Budapest, Hungary and 508 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...
Phase 3
Budapest, Hungary and 508 other locations
This is a Phase III, randomised, open-label, 2 arm, multicentre, international study assessing the efficacy and safety of Dato-DXd compared with ICC...
Phase 3
Budapest, Hungary and 228 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Tatabanya, Hungary and 104 other locations
after induction with first-line chemotherapy plus pembrolizumab in triple negative breast cancer (TNBC). The prim...
Phase 2
Budapest, Hungary and 121 other locations
with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who car...
Phase 3
Budapest, Hungary and 76 other locations
III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...
Phase 3
Budapest, Hungary and 260 other locations
Clinical trials
Research sites
Resources
Legal